Holen Sie sich die Stockscreener-App
5.87
2.65%
-0.16
Handel nachbörslich:
5.80
-0.07
-1.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
New Myriad Genetics Survey Uncovers Women Fear Screenings--But F - GuruFocus
Myriad Genetics Reveals Insights from Cancer Risk Survey Highlighting Women's Attitudes Toward Health Screenings - Quiver Quantitative
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results - GlobeNewswire
Women Want Cancer Genetic Testing But Fear Results: New Health Survey Reveals Critical Gap - Stock Titan
MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance - Yahoo Finance
Myriad Genetics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) - MSN
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
10 Best 52-Week Low Penny Stocks to Buy Now - Insider Monkey
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - MSN
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet and Other Big Stocks Record Gains on Wednesday - AInvest
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings - AInvest
Myriad Genetics shares surge 30.49% in premarket after reporting strong Q2 earnings and raising 2025 revenue guidance. - AInvest
Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance - AInvest
MYRIAD GENETICS INC SEC 10-Q Report - TradingView
Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts - GuruFocus
Myriad Genetics: Leveraging Strategic Overhaul and Market Tailwinds for a Comeback in Precision Medicine - AInvest
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth - AInvest
Myriad Genetics Aims for High Single-Digit to Low Double-Digit Growth through Cancer Care Continuum Focus. - AInvest
Myriad Genetics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Updates 2025 Revenue Guidance Amid Growth - TipRanks
Myriad Genetics (MYGN) Q2 Revenue Up 6% - AOL.com
Myriad Genetics Surges After Hours on Strong Q2 Earnings and Raised Revenue Guidance - AInvest
Transcript : Myriad Genetics, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - inkl
Hold Rating Maintained for Myriad Genetics Amid Mixed Performance and Strategic Challenges - TipRanks
Myriad Genetics Edges Past Estimates And Lifts Revenue Outlook - Finimize
Earnings call transcript: Myriad Genetics beats Q2 2025 expectations with revenue growth - Investing.com Canada
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Myriad: Q2 Earnings Snapshot - San Francisco Chronicle
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c) - TipRanks
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com
Myriad Genetics Reports Q2 Revenue Ahead of Estimates, Stock Jumps 30.6% - AInvest
Myriad Genetics earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% - TradingView
Myriad Genetics Q2 revenue up 1% YoY, raises FY23 guidance. - AInvest
Myriad Genetics Reports Second Quarter 2025 Financial - GlobeNewswire
[8-K] Myriad Genetics Inc Reports Material Event | MYGN SEC FilingForm 8-K - Stock Titan
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum - Yahoo Finance
Prenatal care is evolving with Myriad - WFLA
Price Channel Expanding on Myriad Genetics Inc.’s ChartLow Risk Equity Screener With Results Shared - metal.it
Myriad Genetics Inc. Recovery Likely Here’s What Data ShowsLow Risk Swing Trade Opportunities Identified - metal.it
Myriad Genetics Q2 2025 Earnings: A Pivotal Moment for a Cash-Burning Biotech - AInvest
Earnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow - Yahoo Finance
How strong is Myriad Genetics Inc. company’s balance sheetSuperior profit margins - Jammu Links News
How does Myriad Genetics Inc. generate profit in a changing economyExponential wealth increase - Jammu Links News
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):